United States: Electronic Drug Product Listing Errors Can Result In FDA Warning Letter

Last Updated: July 3 2017
Article by Ann M. Begley, Jacqueline R. Berman and Heather A. Dorsey

FDA Warning Letters focus on inaccurate drug product listings.

Over the last year, the US Food and Drug Administration (FDA or Agency) has increased its enforcement efforts concerning drug product listing requirements, resulting in a number of Warning Letters for what appear to be simple errors in electronic submissions of drug product listings.

The Federal Food, Drug and Cosmetic Act (FFDCA) and FDA's implementing regulations require the listing of all commercially distributed drugs (including active pharmaceutical ingredients).1 In August 2016, FDA finally completed its rulemaking to adopt the 2007 amendment to the FFDCA that requires all drug establishment registration and drug product listing information to be submitted to FDA electronically in the absence of an Agency waiver.2

While FDA has required electronic submission of this information via the electronic drug registration and listing service (eDRLS) for many years, enforcement activity for alleged violations of the listing requirements is fairly recent. Since March 2016, the Agency has issued five Warning Letters based solely on listing violations, two of which were issued in the last month.3 For example, FDA issued Warning Letters for the following submission errors:

  • Failure to update drug listing files to reflect discontinuance of drug products
  • Missing active ingredient and incorrect information
  • Missing copy of the product label
  • Incorrect spelling of the active ingredient
  • Incorrect application number referenced
  • Incorrect proprietary name included in the listing
  • Incorrect quantity for the package size
  • Incorrect strength of active ingredient
  • Failure to include the drug product's Drug Enforcement Agency (DEA) schedule4

In all cases, FDA expressed concern that incorrect drug product listings are accessible to the public, including consumers. In most cases, asserting the need to "protect and promote the public health" by "maintain[ing] a correct and accurate database," and citing misbranding and drug product listing violations under the FFDCA, the Agency immediately removed only the incorrect listings from FDA's National Drug Code (NDC) Directory such that they would not be publicly viewable.5 In one case, however, FDA did not limit removal to just those listings that were incorrect—instead, stating that "FDA's Drug Registration and Listing Staff does not have sufficient resources to check each of [the] drug listing files before the data is published," the Agency refused to make any of the firm's listing files public.6

In addition to mandating correction of the inaccurate information in the drug product listings, FDA required each Warning Letter recipient to provide a plan to prevent a recurrence of the violations.7 In the case of the firm where FDA refused to make any of the firm's listings public, the Agency required, at a minimum, that the response include the following:

  • How the firm reviewed, or plans to review, all current drug listings to identify those listings that need to be updated
  • How the firm corrected, or plans to correct, the identified errors (e.g., submit corrected Structured Product Labeling files for existing listings, delist NDCs no longer in use by submitting end marketing dates and changing marketing status to complete)
  • The plan or process the firm has implemented, or plans to implement, in order to prevent the recurrence of the violations8

Key Takeaways

While FDA occasionally cites noncompliance with the drug listing requirements in its enforcement letters, such observations frequently accompany other, more significant alleged regulatory violations. In these instances, however, the listing violations were the sole focus of FDA's enforcement letters. Moreover, based on the text of the enforcement letters, in some cases, the FDA Warning Letter may have been the first time that the Agency notified the recipient of an issue with its drug listings. Many of the cited violations likely were administrative or clerical oversights that occurred when entering the drug information into the eDRLS.

While listing drugs is perceived as merely an administrative task, failure to list drug products or incorrectly listing products is a violation of the FFDCA, as the Warning Letters reflect. Failure to fulfill listing obligations misbrands the applicable product under the FFDCA,9 and the FFDCA further prohibits the introduction of misbranded products into interstate commerce.10

Taken together, this round of Warning Letters indicates that FDA may be more apt to take public enforcement action based solely on a company's failure to properly list drug products, even in the absence of any other violations, rather than sending private communications regarding errors through the eDRLS staff. The immediate removal of a product from FDA's NDC Directory raises questions about ongoing distribution of the product pending FDA's acceptance of the corrective measures. This situation is more complicated for imported drug products if they are subject to this type of enforcement action, as they may be refused entry into the United States until FDA accepts the corrective action.11

It would appear that FDA is sending a public message to regulated firms regarding the importance of accurate and completed drug product listing submissions. As a result, firms should refamiliarize themselves with FDA's listing requirements, consider reviewing prior electronic drug product listing submissions for accuracy and compliance with FDA regulations, and assess the need for an internal procedure to ensure current listings are appropriately updated and new listings are accurate and complete before submission.


1 FFDCA § 510(j); 21 C.F.R. Part 207, Subpart D.

2 Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs, 81 Fed. Reg. 60169 (Aug. 31, 2016); Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85 (2007).

3 See US Food & Drug Admin., Warning Letter to A-S Medication Solutions (June 5, 2017); US Food & Drug Admin., Warning Letter to Prestige Brand Holdings (June 1, 2017); US Food & Drug Admin., Warning Letter to Exact-Rx (Apr. 19, 2017); US Food & Drug Admin., Warning Letter to Targeted Medical Pharma, Inc., dba Physician Therapeutics (Oct. 6, 2016); US Food & Drug Admin., Warning Letter to Pharmaceutical Associates (Mar. 23, 2016).

4 See supra note 3.

5 See supra note 3.

6 US Food & Drug Admin., Warning Letter to A-S Medication Solutions (June 5, 2017).

7 See supra note 3.

8 See supra note 6.

9 FFDCA § 502(o).

10 FFDCA §§ 301(a), 301(p).

11 US Food & Drug Admin., Importation of Drugs Outline (Sept. 7, 2012).

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.